ID   CTNB1_MOUSE             Reviewed;         781 AA.
AC   Q02248; Q922W1; Q9D335;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   18-JUN-2025, entry version 258.
DE   RecName: Full=Catenin beta-1 {ECO:0000312|MGI:MGI:88276};
DE   AltName: Full=Beta-catenin {ECO:0000303|PubMed:1509266};
GN   Name=Ctnnb1 {ECO:0000312|MGI:MGI:88276};
GN   Synonyms=Catnb {ECO:0000312|MGI:MGI:88276};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1509266; DOI=10.1126/science.257.5073.1142-a;
RA   Butz S., Stappert J., Weissig H., Kemler R.;
RT   "Plakoglobin and beta-catenin: distinct but closely related.";
RL   Science 257:1142-1144(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Colon, and Urinary bladder;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Brain, and Mammary cancer;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   IDENTIFICATION IN AN E-CADHERIN/CATENIN ADHESION COMPLEX.
RX   PubMed=7982500; DOI=10.1016/0014-5793(94)01205-9;
RA   Butz S., Kemler R.;
RT   "Distinct cadherin-catenin complexes in Ca(2+)-dependent cell-cell
RT   adhesion.";
RL   FEBS Lett. 355:195-200(1994).
RN   [5]
RP   INTERACTION WITH TCF7; TCF7L1; TCF7L2 AND LEF1.
RX   PubMed=9783587; DOI=10.1038/26989;
RA   Roose J., Molenaar M., Peterson J., Hurenkamp J., Brantjes H., Moerer P.,
RA   van de Wetering M., Destree O., Clevers H.;
RT   "The Xenopus Wnt effector XTcf-3 interacts with Groucho-related
RT   transcriptional repressors.";
RL   Nature 395:608-612(1998).
RN   [6]
RP   INTERACTION WITH AXIN1.
RX   PubMed=10581160; DOI=10.1006/bbrc.1999.1760;
RA   Jho E., Lomvardas S., Costantini F.;
RT   "A GSK3beta phosphorylation site in axin modulates interaction with beta-
RT   catenin and Tcf-mediated gene expression.";
RL   Biochem. Biophys. Res. Commun. 266:28-35(1999).
RN   [7]
RP   INTERACTION WITH BAIAP1.
RX   PubMed=10772923; DOI=10.1006/bbrc.2000.2471;
RA   Dobrosotskaya I.Y., James G.L.;
RT   "MAGI-1 interacts with beta-catenin and is associated with cell-cell
RT   adhesion structures.";
RL   Biochem. Biophys. Res. Commun. 270:903-909(2000).
RN   [8]
RP   INTERACTION WITH CTNNA3.
RX   PubMed=11590244; DOI=10.1242/jcs.114.17.3177;
RA   Janssens B., Goossens S., Staes K., Gilbert B., van Hengel J., Colpaert C.,
RA   Bruyneel E., Mareel M., van Roy F.;
RT   "AlphaT-catenin: a novel tissue-specific beta-catenin-binding protein
RT   mediating strong cell-cell adhesion.";
RL   J. Cell Sci. 114:3177-3188(2001).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12494996; DOI=10.1078/0171-9335-00278;
RA   Eshkind L., Tian Q., Schmidt A., Franke W.W., Windoffer R., Leube R.E.;
RT   "Loss of desmoglein 2 suggests essential functions for early embryonic
RT   development and proliferation of embryonal stem cells.";
RL   Eur. J. Cell Biol. 81:592-598(2002).
RN   [10]
RP   INTERACTION WITH TAX1BP3.
RX   PubMed=12874278; DOI=10.1074/jbc.m306324200;
RA   Kanamori M., Sandy P., Marzinotto S., Benetti R., Kai C., Hayashizaki Y.,
RA   Schneider C., Suzuki H.;
RT   "The PDZ protein tax-interacting protein-1 inhibits beta-catenin
RT   transcriptional activity and growth of colorectal cancer cells.";
RL   J. Biol. Chem. 278:38758-38764(2003).
RN   [11]
RP   PHOSPHORYLATION AT TYR-142 BY FYN.
RX   PubMed=12640114; DOI=10.1128/mcb.23.7.2287-2297.2003;
RA   Piedra J., Miravet S., Castano J., Palmer H.G., Heisterkamp N.,
RA   Garcia de Herreros A., Dunach M.;
RT   "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin
RT   Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction.";
RL   Mol. Cell. Biol. 23:2287-2297(2003).
RN   [12]
RP   INTERACTION WITH RORA.
RX   PubMed=14687547; DOI=10.1016/s0896-6273(03)00769-4;
RA   Gold D.A., Baek S.H., Schork N.J., Rose D.W., Larsen D.D., Sachs B.D.,
RA   Rosenfeld M.G., Hamilton B.A.;
RT   "RORalpha coordinates reciprocal signaling in cerebellar development
RT   through sonic hedgehog and calcium-dependent pathways.";
RL   Neuron 40:1119-1131(2003).
RN   [13]
RP   INTERACTION WITH AXIN1.
RX   PubMed=15063782; DOI=10.1016/j.bbrc.2004.03.065;
RA   Kim S.I., Park C.S., Lee M.S., Kwon M.S., Jho E.H., Song W.K.;
RT   "Cyclin-dependent kinase 2 regulates the interaction of Axin with beta-
RT   catenin.";
RL   Biochem. Biophys. Res. Commun. 317:478-483(2004).
RN   [14]
RP   FUNCTION, INTERACTION WITH SOX9, AND UBIQUITINATION.
RX   PubMed=15132997; DOI=10.1101/gad.1171104;
RA   Akiyama H., Lyons J.P., Mori-Akiyama Y., Yang X., Zhang R., Zhang Z.,
RA   Deng J.M., Taketo M.M., Nakamura T., Behringer R.R., McCrea P.D.,
RA   de Crombrugghe B.;
RT   "Interactions between Sox9 and beta-catenin control chondrocyte
RT   differentiation.";
RL   Genes Dev. 18:1072-1087(2004).
RN   [15]
RP   RECONSTITUTION OF THE E-CADHERIN/CATENIN ADHESION COMPLEX, LACK OF
RP   ACTIN-BINDING BY THE E-CADHERIN/CATENIN ADHESION COMPLEX, AND FUNCTION.
RX   PubMed=16325582; DOI=10.1016/j.cell.2005.09.020;
RA   Yamada S., Pokutta S., Drees F., Weis W.I., Nelson W.J.;
RT   "Deconstructing the cadherin-catenin-actin complex.";
RL   Cell 123:889-901(2005).
RN   [16]
RP   INTERACTION WITH BCL9L.
RX   PubMed=17052462; DOI=10.1016/j.molcel.2006.09.001;
RA   Sampietro J., Dahlberg C.L., Cho U.S., Hinds T.R., Kimelman D., Xu W.;
RT   "Crystal structure of a beta-catenin/BCL9/Tcf4 complex.";
RL   Mol. Cell 24:293-300(2006).
RN   [17]
RP   INTERACTION WITH GLIS2, AND SUBCELLULAR LOCATION.
RX   PubMed=17289029; DOI=10.1016/j.febslet.2007.01.058;
RA   Kim Y.-S., Kang H.S., Jetten A.M.;
RT   "The Kruppel-like zinc finger protein Glis2 functions as a negative
RT   modulator of the Wnt/beta-catenin signaling pathway.";
RL   FEBS Lett. 581:858-864(2007).
RN   [18]
RP   INTERACTION WITH XIRP1.
RX   PubMed=17925400; DOI=10.1074/jbc.m707639200;
RA   Choi S., Gustafson-Wagner E.A., Wang Q., Harlan S.M., Sinn H.W.,
RA   Lin J.L.-C., Lin J.J.-C.;
RT   "The intercalated disc protein, mXin{alpha}, is capable of interacting with
RT   beta-catenin and bundling actin filaments.";
RL   J. Biol. Chem. 282:36024-36036(2007).
RN   [19]
RP   INTERACTION WITH SLC30A9.
RX   PubMed=17344318; DOI=10.1093/nar/gkm095;
RA   Chen Y.H., Yang C.K., Xia M., Ou C.Y., Stallcup M.R.;
RT   "Role of GAC63 in transcriptional activation mediated by beta-catenin.";
RL   Nucleic Acids Res. 35:2084-2092(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-191; SER-552 AND SER-675, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [21]
RP   LACK OF ACTIN-BINDING BY THE E-CADHERIN/CATENIN ADHESION COMPLEX, AND
RP   FUNCTION.
RX   PubMed=18093941; DOI=10.1073/pnas.0710504105;
RA   Abe K., Takeichi M.;
RT   "EPLIN mediates linkage of the cadherin catenin complex to F-actin and
RT   stabilizes the circumferential actin belt.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:13-19(2008).
RN   [22]
RP   INTERACTION WITH TCF7L2 AND TNIK.
RX   PubMed=19816403; DOI=10.1038/emboj.2009.285;
RA   Mahmoudi T., Li V.S.W., Ng S.S., Taouatas N., Vries R.G.J., Mohammed S.,
RA   Heck A.J., Clevers H.;
RT   "The kinase TNIK is an essential activator of Wnt target genes.";
RL   EMBO J. 28:3329-3340(2009).
RN   [23]
RP   INTERACTION WITH SCRIB.
RX   PubMed=19458197; DOI=10.1091/mbc.e08-12-1172;
RA   Sun Y., Aiga M., Yoshida E., Humbert P.O., Bamji S.X.;
RT   "Scribble interacts with beta-catenin to localize synaptic vesicles to
RT   synapses.";
RL   Mol. Biol. Cell 20:3390-3400(2009).
RN   [24]
RP   PHOSPHORYLATION AT SER-33 AND SER-37 BY HIPK2, AND MUTAGENESIS OF SER-33
RP   AND SER-37.
RX   PubMed=20307497; DOI=10.1016/j.bbrc.2010.03.099;
RA   Kim E.-A., Kim J.E., Sung K.S., Choi D.W., Lee B.J., Choi C.Y.;
RT   "Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for
RT   phosphorylation and proteasomal degradation.";
RL   Biochem. Biophys. Res. Commun. 394:966-971(2010).
RN   [25]
RP   PHOSPHORYLATION AT SER-552, AND MUTAGENESIS OF SER-552.
RX   PubMed=20361929; DOI=10.1016/j.bbrc.2010.03.161;
RA   Zhao J., Yue W., Zhu M.J., Sreejayan N., Du M.;
RT   "AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt
RT   signaling via phosphorylation of beta-catenin at Ser 552.";
RL   Biochem. Biophys. Res. Commun. 395:146-151(2010).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-45; SER-191 AND SER-675, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung,
RC   Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [27]
RP   INTERACTION WITH TRPV4 AND CDH1.
RX   PubMed=20413591; DOI=10.1074/jbc.m110.103606;
RA   Sokabe T., Fukumi-Tominaga T., Yonemura S., Mizuno A., Tominaga M.;
RT   "The TRPV4 channel contributes to intercellular junction formation in
RT   keratinocytes.";
RL   J. Biol. Chem. 285:18749-18758(2010).
RN   [28]
RP   INTERACTION WITH VCL, AND MUTAGENESIS OF MET-8.
RX   PubMed=20086044; DOI=10.1242/jcs.056432;
RA   Peng X., Cuff L.E., Lawton C.D., DeMali K.A.;
RT   "Vinculin regulates cell-surface E-cadherin expression by binding to beta-
RT   catenin.";
RL   J. Cell Sci. 123:567-577(2010).
RN   [29]
RP   REVIEW.
RX   PubMed=10679188; DOI=10.1006/bbrc.1999.1860;
RA   Kikuchi A.;
RT   "Regulation of beta-catenin signaling in the Wnt pathway.";
RL   Biochem. Biophys. Res. Commun. 268:243-248(2000).
RN   [30]
RP   S-NITROSYLATION AT CYS-619, AND SUBCELLULAR LOCATION.
RX   PubMed=20705246; DOI=10.1016/j.molcel.2010.07.013;
RA   Thibeault S., Rautureau Y., Oubaha M., Faubert D., Wilkes B.C., Delisle C.,
RA   Gratton J.P.;
RT   "S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced
RT   endothelial cell permeability.";
RL   Mol. Cell 39:468-476(2010).
RN   [31]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND CONDITIONAL KNOCKOUT.
RX   PubMed=21325504; DOI=10.1523/jneurosci.4243-10.2011;
RA   Armstrong A., Ryu Y.K., Chieco D., Kuruvilla R.;
RT   "Frizzled3 is required for neurogenesis and target innervation during
RT   sympathetic nervous system development.";
RL   J. Neurosci. 31:2371-2381(2011).
RN   [32]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=21623382; DOI=10.1038/nm.2380;
RA   Lancaster M.A., Gopal D.J., Kim J., Saleem S.N., Silhavy J.L., Louie C.M.,
RA   Thacker B.E., Williams Y., Zaki M.S., Gleeson J.G.;
RT   "Defective Wnt-dependent cerebellar midline fusion in a mouse model of
RT   Joubert syndrome.";
RL   Nat. Med. 17:726-731(2011).
RN   [33]
RP   TISSUE SPECIFICITY.
RX   PubMed=22510880; DOI=10.1038/emboj.2012.91;
RA   Wilson C.H., Crombie C., van der Weyden L., Poulogiannis G., Rust A.G.,
RA   Pardo M., Gracia T., Yu L., Choudhary J., Poulin G.B., McIntyre R.E.,
RA   Winton D.J., March H.N., Arends M.J., Fraser A.G., Adams D.J.;
RT   "Nuclear receptor binding protein 1 regulates intestinal progenitor cell
RT   homeostasis and tumour formation.";
RL   EMBO J. 31:2486-2497(2012).
RN   [34]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH DLG5.
RX   PubMed=25232112; DOI=10.1523/jneurosci.1280-14.2014;
RA   Wang S.H., Celic I., Choi S.Y., Riccomagno M., Wang Q., Sun L.O.,
RA   Mitchell S.P., Vasioukhin V., Huganir R.L., Kolodkin A.L.;
RT   "Dlg5 regulates dendritic spine formation and synaptogenesis by controlling
RT   subcellular N-cadherin localization.";
RL   J. Neurosci. 34:12745-12761(2014).
RN   [35]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25979161; DOI=10.1016/j.bone.2015.05.009;
RA   Jeong B.C., Kim T.S., Kim H.S., Lee S.H., Choi Y.;
RT   "Transmembrane protein 64 reciprocally regulates osteoblast and adipocyte
RT   differentiation by modulating Wnt/beta-catenin signaling.";
RL   Bone 78:165-173(2015).
RN   [36]
RP   SUBCELLULAR LOCATION.
RX   PubMed=27375112; DOI=10.1016/j.jid.2016.05.124;
RA   Keil R., Rietscher K., Hatzfeld M.;
RT   "Antagonistic Regulation of Intercellular Cohesion by Plakophilins 1 and
RT   3.";
RL   J. Invest. Dermatol. 136:2022-2029(2016).
RN   [37]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=27015268; DOI=10.1371/journal.pone.0152206;
RA   Miyazaki K., Yoshizaki K., Arai C., Yamada A., Saito K., Ishikawa M.,
RA   Xue H., Funada K., Haruyama N., Yamada Y., Fukumoto S., Takahashi I.;
RT   "Plakophilin-1, a Novel Wnt Signaling Regulator, Is Critical for Tooth
RT   Development and Ameloblast Differentiation.";
RL   PLoS ONE 11:e0152206-e0152206(2016).
RN   [38]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=29148101; DOI=10.1111/eos.12390;
RA   Feng X.Y., Wu X.S., Wang J.S., Zhang C.M., Wang S.L.;
RT   "Homeobox protein MSX-1 inhibits expression of bone morphogenetic protein
RT   2, bone morphogenetic protein 4, and lymphoid enhancer-binding factor 1 via
RT   Wnt/beta-catenin signaling to prevent differentiation of dental mesenchymal
RT   cells during the late bell stage.";
RL   Eur. J. Oral Sci. 126:1-12(2018).
RN   [39]
RP   SUBCELLULAR LOCATION.
RX   PubMed=30389919; DOI=10.1038/s41467-018-06941-4;
RA   Koren E., Yosefzon Y., Ankawa R., Soteriou D., Jacob A., Nevelsky A.,
RA   Ben-Yosef R., Bar-Sela G., Fuchs Y.;
RT   "ARTS mediates apoptosis and regeneration of the intestinal stem cell
RT   niche.";
RL   Nat. Commun. 9:4582-4582(2018).
RN   [40]
RP   INTERACTION WITH LMBR1L AND AMFR.
RX   PubMed=31073040; DOI=10.1126/science.aau0812;
RA   Choi J.H., Zhong X., McAlpine W., Liao T.C., Zhang D., Fang B., Russell J.,
RA   Ludwig S., Nair-Gill E., Zhang Z., Wang K.W., Misawa T., Zhan X., Choi M.,
RA   Wang T., Li X., Tang M., Sun Q., Yu L., Murray A.R., Moresco E.M.Y.,
RA   Beutler B.;
RT   "LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling.";
RL   Science 364:0-0(2019).
RN   [41]
RP   INTERACTION WITH ADNP.
RX   PubMed=32533114; DOI=10.1038/s41467-020-16799-0;
RA   Sun X., Peng X., Cao Y., Zhou Y., Sun Y.;
RT   "ADNP promotes neural differentiation by modulating Wnt/beta-catenin
RT   signaling.";
RL   Nat. Commun. 11:2984-2984(2020).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 150-665.
RX   PubMed=9298899; DOI=10.1016/s0092-8674(00)80352-9;
RA   Huber A.H., Nelson W.J., Weis W.I.;
RT   "Three-dimensional structure of the armadillo repeat region of beta-
RT   catenin.";
RL   Cell 90:871-882(1997).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 118-149 IN COMPLEX WITH CTNNA1.
RX   PubMed=10882138; DOI=10.1016/s1097-2765(00)80447-5;
RA   Pokutta S., Weis W.I.;
RT   "Structure of the dimerization and beta-catenin-binding region of alpha-
RT   catenin.";
RL   Mol. Cell 5:533-543(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.0 AND 3.0 ANGSTROMS) OF 134-671 IN COMPLEX WITH
RP   PHOSPHORYLATED AND UNPHOSPHORYLATED CDH1.
RX   PubMed=11348595; DOI=10.1016/s0092-8674(01)00330-0;
RA   Huber A.H., Weis W.I.;
RT   "The structure of the beta-catenin/E-cadherin complex and the molecular
RT   basis of diverse ligand recognition by beta-catenin.";
RL   Cell 105:391-402(2001).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 134-671 IN COMPLEX WITH APC.
RX   PubMed=11707392; DOI=10.1093/emboj/20.22.6203;
RA   Eklof Spink K., Fridman S.G., Weis W.I.;
RT   "Molecular mechanisms of beta-catenin recognition by adenomatous polyposis
RT   coli revealed by the structure of an APC-beta-catenin complex.";
RL   EMBO J. 20:6203-6212(2001).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 134-671 IN COMPLEX WITH CTNNBIP1,
RP   AND INTERACTION WITH EP300.
RX   PubMed=12408825; DOI=10.1016/s1097-2765(02)00631-7;
RA   Daniels D.L., Weis W.I.;
RT   "ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors
RT   and the general coactivator p300 using independent structural modules.";
RL   Mol. Cell 10:573-584(2002).
CC   -!- FUNCTION: Key downstream component of the canonical Wnt signaling
CC       pathway (PubMed:15132997). In the absence of Wnt, forms a complex with
CC       AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on
CC       N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC
CC       and its subsequent degradation by the proteasome. In the presence of
CC       Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus,
CC       where it acts as a coactivator for transcription factors of the TCF/LEF
CC       family, leading to activate Wnt responsive genes (By similarity). Also
CC       acts as a coactivator for other transcription factors, such as NR5A2
CC       (By similarity). Promotes epithelial to mesenchymal
CC       transition/mesenchymal to epithelial transition (EMT/MET) via driving
CC       transcription of CTNNB1/TCF-target genes (By similarity). Involved in
CC       the regulation of cell adhesion, as component of an E-cadherin:catenin
CC       adhesion complex (PubMed:16325582, PubMed:18093941). Acts as a negative
CC       regulator of centrosome cohesion. Involved in the
CC       CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks
CC       anoikis of malignant kidney and intestinal epithelial cells and
CC       promotes their anchorage-independent growth by down-regulating DAPK2.
CC       Disrupts PML function and PML-NB formation by inhibiting RANBP2-
CC       mediated sumoylation of PML (By similarity). Promotes neurogenesis by
CC       maintaining sympathetic neuroblasts within the cell cycle
CC       (PubMed:21325504). Involved in chondrocyte differentiation via
CC       interaction with SOX9: SOX9-binding competes with the binding sites of
CC       TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling
CC       (PubMed:15132997). Acts as a positive regulator of odontoblast
CC       differentiation during mesenchymal tooth germ formation, via promoting
CC       the transcription of differentiation factors such as LEF1, BMP2 and
CC       BMP4 (PubMed:29148101). Activity is repressed in a MSX1-mediated manner
CC       at the bell stage of mesenchymal tooth germ formation which prevents
CC       premature differentiation of odontoblasts (PubMed:29148101).
CC       {ECO:0000250|UniProtKB:P35222, ECO:0000269|PubMed:15132997,
CC       ECO:0000269|PubMed:16325582, ECO:0000269|PubMed:18093941,
CC       ECO:0000269|PubMed:21325504, ECO:0000269|PubMed:29148101}.
CC   -!- SUBUNIT: Two separate complex-associated pools are found in the
CC       cytoplasm. The majority is present as component of an E-cadherin/
CC       catenin adhesion complex composed of at least E-cadherin/CDH1 and beta-
CC       catenin/CTNNB1, and possibly alpha-catenin/CTNNA1; the complex is
CC       located to adherens junctions. The stable association of CTNNA1 is
CC       controversial as CTNNA1 was shown not to bind to F-actin when assembled
CC       in the complex. Alternatively, the CTNNA1-containing complex may be
CC       linked to F-actin by other proteins such as LIMA1. Binds NHERF1.
CC       Interacts with PTPRU (via the cytoplasmic juxtamembrane domain) and
CC       with EMD. Interacts with SESTD1 and TRPC4. Interacts with CAV1.
CC       Interacts with PTPRJ. Interacts with PKT7. Interacts with FAT1 (via the
CC       cytoplasmic domain). Interacts with CDK2, NDRG2 and NANOS1. Interacts
CC       with NEK2 and CDK5. Interacts with CARM1, CXADR, PCDH11Y and PTK6.
CC       Interacts with RAPGEF2. Interacts with SOX7; this interaction may lead
CC       to proteasomal degradation of active CTNNB1 and thus inhibition of
CC       Wnt/beta-catenin-stimulated transcription. Identified in a complex with
CC       HINT1 and MITF. Interacts with FHIT. Interacts with FERMT2. Identified
CC       in a complex with TCF4 and FERMT2. Another cytoplasmic pool is part of
CC       a large complex containing AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that
CC       promotes phosphorylation on N-terminal Ser and Thr residues and
CC       ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the
CC       proteasome. Wnt-dependent activation of DVL antagonizes the action of
CC       GSK3B. When GSK3B activity is inhibited the complex dissociates, CTNNB1
CC       is dephosphorylated and is no longer targeted for destruction. The
CC       stabilized protein translocates to the nucleus, where it binds TCF/LEF-
CC       1 family members, BCL9, BCL9L and possibly also RUVBL1 and CHD8.
CC       Interacts with TAX1BP3 (via the PDZ domain); this interaction inhibits
CC       the transcriptional activity of CTNNB1. Interacts with AJAP1, BAIAP1
CC       and CTNNA3. Interacts with TRPV4; the TRPV4 and CTNNB1 complex can
CC       interact with CDH1. Interacts with VCL. The CTNNB1 and TCF4 complex
CC       interacts with PML. Interacts with XIRP1. Binds CTNNBIP and EP300.
CC       CTNNB1 forms a ternary complex with LEF1 and EP300 that is disrupted by
CC       CTNNBIP1 binding. Interacts directly with AXIN1; the interaction is
CC       regulated by CDK2 phosphorylation of AXIN1. Interacts with GLIS2.
CC       Interacts with SCRIB. Interacts with TNIK and TCF7L2. Interacts with
CC       SLC30A9. Interacts with RORA. May interact with P-cadherin/CDH3.
CC       Interacts with RNF220 (By similarity). Interacts with CTNND2 (By
CC       similarity). Interacts (via the C-terminal region) with CBY1 (By
CC       similarity). The complex composed, at least, of APC, CTNNB1 and GSK3B
CC       interacts with JPT1; the interaction requires the inactive form of
CC       GSK3B (phosphorylated at 'Ser-9') (By similarity). Interacts with DLG5
CC       (PubMed:25232112). Interacts with FAM53B; promoting translocation to
CC       the nucleus. Interacts with TMEM170B (By similarity). Interacts with
CC       AHI1 (By similarity). Interacts with GID8 (By similarity). Component of
CC       an cadherin:catenin adhesion complex composed of at least of CDH26,
CC       beta-catenin/CTNNB1, alpha-catenin/CTNNA1 and p120 catenin/CTNND1 (By
CC       similarity). Forms a complex comprising APPL1, RUVBL2, APPL2, HDAC1 and
CC       HDAC2 (By similarity). Interacts with IRF2BPL; mediates the
CC       ubiquitination and degradation of CTNNB1 (By similarity). Interacts
CC       with AMFR (PubMed:31073040). Interacts with LMBR1L (PubMed:31073040).
CC       Interacts with SOX30; prevents interaction of CTNNB1 with TCF7L2/TCF4
CC       and leads to inhibition of Wnt signaling (By similarity). Interacts
CC       with SOX9; inhibiting CTNNB1 activity by competing with the binding
CC       sites of TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling
CC       (PubMed:15132997). Interacts with SPN/CD43 cytoplasmic tail (By
CC       similarity). Interacts (when phosphorylated at Tyr-333) with isoform M2
CC       of PKM (PKM2); promoting transcription activation (By similarity).
CC       Interacts with PKP2 (via HEAD domain) (By similarity). Interacts with
CC       CDH1 (By similarity). Interacts (when unphosphorylated) with FLYWCH1,
CC       perhaps preventing interaction of CTNNB1 with TCF4, and thereby
CC       regulating transcription activation; phosphorylation of CTNNB1 may
CC       inhibit the interaction (By similarity). Interacts (via the central
CC       armadillo domains) with probable transcriptional regulator ADNP (via N-
CC       terminal region); interaction is direct and stabilizes CTNNB1 by
CC       modulating its phosphorylation by glycogen synthase kinase-3 beta GSK3B
CC       (PubMed:32533114). Interacts with NR5A2 (By similarity). Interacts with
CC       DSG2; the interaction promotes localization of CTNNB1 at cell junctions
CC       thus reducing its nuclear localization and subsequent transcription of
CC       CTNNB1/TCF-target genes (By similarity). {ECO:0000250|UniProtKB:P35222,
CC       ECO:0000269|PubMed:10581160, ECO:0000269|PubMed:10772923,
CC       ECO:0000269|PubMed:10882138, ECO:0000269|PubMed:11348595,
CC       ECO:0000269|PubMed:11590244, ECO:0000269|PubMed:11707392,
CC       ECO:0000269|PubMed:12408825, ECO:0000269|PubMed:12874278,
CC       ECO:0000269|PubMed:14687547, ECO:0000269|PubMed:15063782,
CC       ECO:0000269|PubMed:15132997, ECO:0000269|PubMed:17052462,
CC       ECO:0000269|PubMed:17289029, ECO:0000269|PubMed:17344318,
CC       ECO:0000269|PubMed:17925400, ECO:0000269|PubMed:19458197,
CC       ECO:0000269|PubMed:19816403, ECO:0000269|PubMed:20086044,
CC       ECO:0000269|PubMed:20413591, ECO:0000269|PubMed:25232112,
CC       ECO:0000269|PubMed:31073040, ECO:0000269|PubMed:32533114,
CC       ECO:0000269|PubMed:7982500, ECO:0000269|PubMed:9783587}.
CC   -!- INTERACTION:
CC       Q02248; P09803: Cdh1; NbExp=17; IntAct=EBI-397872, EBI-984420;
CC       Q02248; P45481: Crebbp; NbExp=3; IntAct=EBI-397872, EBI-296306;
CC       Q02248; P26231: Ctnna1; NbExp=2; IntAct=EBI-397872, EBI-647895;
CC       Q02248; Q9WV60: Gsk3b; NbExp=2; IntAct=EBI-397872, EBI-400793;
CC       Q02248; P42859: Htt; NbExp=3; IntAct=EBI-397872, EBI-5327353;
CC       Q02248; P27782: Lef1; NbExp=6; IntAct=EBI-397872, EBI-984464;
CC       Q02248; O54826: Mllt10; NbExp=2; IntAct=EBI-397872, EBI-8459555;
CC       Q02248; P97458: Prop1; NbExp=2; IntAct=EBI-397872, EBI-937831;
CC       Q02248; Q04207: Rela; NbExp=5; IntAct=EBI-397872, EBI-644400;
CC       Q02248; P40645: Sox6; NbExp=2; IntAct=EBI-397872, EBI-3505685;
CC       Q02248; Q9DBG9: Tax1bp3; NbExp=6; IntAct=EBI-397872, EBI-1161647;
CC       Q02248; P25054: APC; Xeno; NbExp=8; IntAct=EBI-397872, EBI-727707;
CC       Q02248; O15169: AXIN1; Xeno; NbExp=5; IntAct=EBI-397872, EBI-710484;
CC       Q02248; Q9NSA3: CTNNBIP1; Xeno; NbExp=7; IntAct=EBI-397872, EBI-747082;
CC       Q02248; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-397872, EBI-373586;
CC       Q02248; F1MSG6: RAPGEF2; Xeno; NbExp=2; IntAct=EBI-397872, EBI-6927068;
CC       Q02248; O15047: SETD1A; Xeno; NbExp=2; IntAct=EBI-397872, EBI-540779;
CC       Q02248; P33148; Xeno; NbExp=4; IntAct=EBI-397872, EBI-15603953;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:27015268,
CC       ECO:0000269|PubMed:27375112, ECO:0000269|PubMed:30389919}. Nucleus
CC       {ECO:0000269|PubMed:27015268, ECO:0000269|PubMed:30389919}. Cytoplasm,
CC       cytoskeleton. Cell junction, adherens junction
CC       {ECO:0000269|PubMed:20705246, ECO:0000269|PubMed:27375112}. Cell
CC       junction {ECO:0000269|PubMed:12494996}. Cell membrane
CC       {ECO:0000269|PubMed:27015268}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000250|UniProtKB:P35222}.
CC       Cytoplasm, cytoskeleton, spindle pole {ECO:0000250|UniProtKB:P35222}.
CC       Synapse {ECO:0000269|PubMed:20705246}. Cytoplasm, cytoskeleton, cilium
CC       basal body {ECO:0000269|PubMed:21623382}. Note=Colocalized with RAPGEF2
CC       and TJP1 at cell-cell contacts (By similarity). Cytoplasmic when it is
CC       un-stable (highly phosphorylated) or bound to CDH1. Translocates to the
CC       nucleus when it is stabilized (low level of phosphorylation).
CC       Interaction with GLIS2 and MUC1 promotes nuclear translocation.
CC       Interaction with EMD inhibits nuclear localization. The majority of
CC       CTNNB1 is localized to the cell membrane. In interphase, colocalizes
CC       with CROCC between CEP250 puncta at the proximal end of centrioles, and
CC       this localization is dependent on CROCC and CEP250. In mitosis, when
CC       NEK2 activity increases, it localizes to centrosomes at spindle poles
CC       independent of CROCC. Colocalizes with CDK5 in the cell-cell contacts
CC       and plasma membrane of undifferentiated and differentiated
CC       neuroblastoma cells. Interaction with FAM53B promotes translocation to
CC       the nucleus (By similarity). Translocates to the nucleus in the
CC       presence of SNAIL1 (By similarity). Ca(2+)-mediated localization to the
CC       cell membrane in dental epithelial cells is inhibited via WNT3A
CC       (PubMed:27015268). Localizes to cell-cell contacts as keratinocyte
CC       differentiation progresses (PubMed:27375112).
CC       {ECO:0000250|UniProtKB:B6V8E6, ECO:0000250|UniProtKB:P35222,
CC       ECO:0000269|PubMed:27015268, ECO:0000269|PubMed:27375112}.
CC   -!- TISSUE SPECIFICITY: Expressed in cerebellar granule neurons (at protein
CC       level) (PubMed:21623382). Expressed in the intestinal epithelium (at
CC       protein level) (PubMed:22510880). Abundantly expressed in the tooth,
CC       skin, lung, kidney, eye and brain with weak expression in the liver and
CC       heart (PubMed:27015268). {ECO:0000269|PubMed:21623382,
CC       ECO:0000269|PubMed:22510880, ECO:0000269|PubMed:27015268}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at 11 dpc in teeth, expression broadly
CC       increases until birth (PubMed:27015268). After birth expression
CC       decreases until 1 week of age (PubMed:27015268). Expressed in
CC       epithelial cells of the tooth germ at 13 dpc (at protein level).
CC       Expressed in the dental epithelium and stellate reticulum at 16 dpc (at
CC       protein level) (PubMed:27015268). Expressed in bell stage dental
CC       mesenchymal cells at 17.5 dpc (at protein level) (PubMed:29148101).
CC       Expressed in both the dental epithelium and dental papilla at birth (at
CC       protein level) (PubMed:27015268). {ECO:0000269|PubMed:27015268,
CC       ECO:0000269|PubMed:29148101}.
CC   -!- PTM: Phosphorylation at Ser-552 by AMPK promotes stabilization of the
CC       protein, enhancing TCF/LEF-mediated transcription (PubMed:20361929).
CC       Phosphorylation by GSK3B requires prior phosphorylation of Ser-45 by
CC       another kinase (By similarity). Phosphorylation proceeds then from Thr-
CC       41 to Ser-37 and Ser-33 (By similarity). Phosphorylated by NEK2 (By
CC       similarity). EGF stimulates tyrosine phosphorylation (By similarity).
CC       Phosphorylated on Ser-33 and Ser-37 by HIPK2 and GSK3B, this
CC       phosphorylation triggers proteasomal degradation (PubMed:20307497).
CC       Phosphorylation on Ser-191 and Ser-246 by CDK5 (By similarity).
CC       Phosphorylation by CDK2 regulates insulin internalization (By
CC       similarity). Phosphorylation by PTK6 at Tyr-64, Tyr-142, Tyr-331 and/or
CC       Tyr-333 with the predominant site at Tyr-64 is not essential for
CC       inhibition of transcriptional activity (By similarity). Phosphorylation
CC       by SRC at Tyr-333 promotes interaction with isoform M2 of PKM (PKM2);
CC       promoting transcription activation (By similarity).
CC       {ECO:0000250|UniProtKB:P35222, ECO:0000269|PubMed:20307497,
CC       ECO:0000269|PubMed:20361929}.
CC   -!- PTM: Ubiquitinated by the SCF(BTRC) E3 ligase complex when
CC       phosphorylated by GSK3B, leading to its degradation (By similarity).
CC       Ubiquitinated by a E3 ubiquitin ligase complex containing UBE2D1,
CC       SIAH1, CACYBP/SIP, SKP1, APC and TBL1X, leading to its subsequent
CC       proteasomal degradation (By similarity). Ubiquitinated and degraded
CC       following interaction with SOX9 (PubMed:15132997). Ubiquitinated via
CC       'Lys-11'- and 'Lys-29'-linked ubiquitin chains by UBR5, leading to its
CC       stabilization (By similarity). {ECO:0000250|UniProtKB:P35222,
CC       ECO:0000305|PubMed:15132997}.
CC   -!- PTM: S-nitrosylation at Cys-619 within adherens junctions promotes
CC       VEGF-induced, NO-dependent endothelial cell permeability by disrupting
CC       interaction with E-cadherin, thus mediating disassembly adherens
CC       junctions. {ECO:0000269|PubMed:20705246}.
CC   -!- PTM: O-glycosylation at Ser-23 decreases nuclear localization and
CC       transcriptional activity, and increases localization to the plasma
CC       membrane and interaction with E-cadherin CDH1.
CC       {ECO:0000250|UniProtKB:Q96S06}.
CC   -!- PTM: Deacetylated at Lys-49 by SIRT1. {ECO:0000250|UniProtKB:P35222}.
CC   -!- DISRUPTION PHENOTYPE: Sympathetic ganglia-specific conditional knockout
CC       mice lead to a reduction in sympathetic ganglia size and in progenitor
CC       cell number, but does not alter sympathetic innervation of peripheral
CC       target organs. {ECO:0000269|PubMed:21325504}.
CC   -!- SIMILARITY: Belongs to the beta-catenin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH06739.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M90364; AAA37280.1; -; mRNA.
DR   EMBL; AK035311; BAC29027.1; -; mRNA.
DR   EMBL; AK018515; BAB31250.1; -; mRNA.
DR   EMBL; BC006739; AAH06739.1; ALT_INIT; mRNA.
DR   EMBL; BC048153; AAH48153.1; -; mRNA.
DR   EMBL; BC053065; AAH53065.1; -; mRNA.
DR   CCDS; CCDS23630.1; -.
DR   PIR; S35091; S35091.
DR   RefSeq; NP_001159374.1; NM_001165902.2.
DR   RefSeq; NP_001418600.1; NM_001431671.1.
DR   RefSeq; NP_001418601.1; NM_001431672.1.
DR   RefSeq; NP_001418602.1; NM_001431673.1.
DR   RefSeq; NP_031640.1; NM_007614.4.
DR   PDB; 1DOW; X-ray; 1.80 A; B=118-149.
DR   PDB; 1I7W; X-ray; 2.00 A; A/C=134-671.
DR   PDB; 1I7X; X-ray; 3.00 A; A/C=134-671.
DR   PDB; 1JPP; X-ray; 3.10 A; A/B=134-671.
DR   PDB; 1M1E; X-ray; 2.10 A; A=134-671.
DR   PDB; 1V18; X-ray; 2.10 A; A=134-671.
DR   PDB; 2BCT; X-ray; 2.90 A; A=150-665.
DR   PDB; 3BCT; X-ray; 2.10 A; A=193-661.
DR   PDB; 3OUW; X-ray; 2.91 A; A=134-671.
DR   PDB; 3OUX; X-ray; 2.40 A; A=134-671.
DR   PDB; 4EV8; X-ray; 1.90 A; A=134-671.
DR   PDB; 4EV9; X-ray; 2.10 A; A=134-671.
DR   PDB; 4EVA; X-ray; 2.00 A; A/C=134-671.
DR   PDB; 4EVP; X-ray; 2.26 A; A=134-671.
DR   PDB; 4EVT; X-ray; 2.34 A; A=134-671.
DR   PDB; 4ONS; X-ray; 2.80 A; B/D=78-151.
DR   PDBsum; 1DOW; -.
DR   PDBsum; 1I7W; -.
DR   PDBsum; 1I7X; -.
DR   PDBsum; 1JPP; -.
DR   PDBsum; 1M1E; -.
DR   PDBsum; 1V18; -.
DR   PDBsum; 2BCT; -.
DR   PDBsum; 3BCT; -.
DR   PDBsum; 3OUW; -.
DR   PDBsum; 3OUX; -.
DR   PDBsum; 4EV8; -.
DR   PDBsum; 4EV9; -.
DR   PDBsum; 4EVA; -.
DR   PDBsum; 4EVP; -.
DR   PDBsum; 4EVT; -.
DR   PDBsum; 4ONS; -.
DR   AlphaFoldDB; Q02248; -.
DR   SMR; Q02248; -.
DR   BioGRID; 198512; 131.
DR   ComplexPortal; CPX-318; beta1-catenin - LEF1 complex.
DR   ComplexPortal; CPX-86; Beta-catenin-ICAT complex.
DR   CORUM; Q02248; -.
DR   DIP; DIP-31560N; -.
DR   FunCoup; Q02248; 2755.
DR   IntAct; Q02248; 79.
DR   MINT; Q02248; -.
DR   STRING; 10090.ENSMUSP00000007130; -.
DR   BindingDB; Q02248; -.
DR   ChEMBL; CHEMBL4105846; -.
DR   TCDB; 8.A.160.2.1; the catenin (catenin) family.
DR   GlyCosmos; Q02248; 1 site, No reported glycans.
DR   GlyGen; Q02248; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (3 sites).
DR   iPTMnet; Q02248; -.
DR   MetOSite; Q02248; -.
DR   PhosphoSitePlus; Q02248; -.
DR   SwissPalm; Q02248; -.
DR   jPOST; Q02248; -.
DR   PaxDb; 10090-ENSMUSP00000007130; -.
DR   PeptideAtlas; Q02248; -.
DR   ProteomicsDB; 285221; -.
DR   Pumba; Q02248; -.
DR   Antibodypedia; 3432; 5149 antibodies from 58 providers.
DR   DNASU; 12387; -.
DR   Ensembl; ENSMUST00000007130.15; ENSMUSP00000007130.9; ENSMUSG00000006932.18.
DR   Ensembl; ENSMUST00000178812.9; ENSMUSP00000136294.2; ENSMUSG00000006932.18.
DR   GeneID; 12387; -.
DR   KEGG; mmu:12387; -.
DR   UCSC; uc009scu.2; mouse.
DR   AGR; MGI:88276; -.
DR   CTD; 1499; -.
DR   MGI; MGI:88276; Ctnnb1.
DR   VEuPathDB; HostDB:ENSMUSG00000006932; -.
DR   eggNOG; KOG4203; Eukaryota.
DR   GeneTree; ENSGT00940000155471; -.
DR   HOGENOM; CLU_008757_1_1_1; -.
DR   InParanoid; Q02248; -.
DR   OMA; YPKLVYT; -.
DR   OrthoDB; 195736at2759; -.
DR   PhylomeDB; Q02248; -.
DR   TreeFam; TF317997; -.
DR   Reactome; R-MMU-195253; Degradation of beta-catenin by the destruction complex.
DR   Reactome; R-MMU-196299; Beta-catenin phosphorylation cascade.
DR   Reactome; R-MMU-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-MMU-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-MMU-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production.
DR   Reactome; R-MMU-351906; Apoptotic cleavage of cell adhesion proteins.
DR   Reactome; R-MMU-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-MMU-4086398; Ca2+ pathway.
DR   Reactome; R-MMU-418990; Adherens junctions interactions.
DR   Reactome; R-MMU-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-MMU-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-MMU-525793; Myogenesis.
DR   Reactome; R-MMU-5626467; RHO GTPases activate IQGAPs.
DR   Reactome; R-MMU-8951430; RUNX3 regulates WNT signaling.
DR   Reactome; R-MMU-9762292; Regulation of CDH11 function.
DR   Reactome; R-MMU-9825892; Regulation of MITF-M-dependent genes involved in cell cycle and proliferation.
DR   BioGRID-ORCS; 12387; 5 hits in 83 CRISPR screens.
DR   CD-CODE; 01CA17F3; Centrosome.
DR   CD-CODE; CE726F99; Postsynaptic density.
DR   ChiTaRS; Ctnnb1; mouse.
DR   EvolutionaryTrace; Q02248; -.
DR   PRO; PR:Q02248; -.
DR   Proteomes; UP000000589; Chromosome 9.
DR   RNAct; Q02248; protein.
DR   Bgee; ENSMUSG00000006932; Expressed in primitive streak and 308 other cell types or tissues.
DR   ExpressionAtlas; Q02248; baseline and differential.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0043296; C:apical junction complex; IDA:MGI.
DR   GO; GO:0045177; C:apical part of cell; IDA:MGI.
DR   GO; GO:0016327; C:apicolateral plasma membrane; IDA:MGI.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:MGI.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:MGI.
DR   GO; GO:1990711; C:beta-catenin-ICAT complex; IPI:ComplexPortal.
DR   GO; GO:1990907; C:beta-catenin-TCF complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070369; C:beta-catenin-TCF7L2 complex; ISS:UniProtKB.
DR   GO; GO:0005923; C:bicellular tight junction; IDA:MGI.
DR   GO; GO:0016342; C:catenin complex; IDA:MGI.
DR   GO; GO:0005938; C:cell cortex; ISS:UniProtKB.
DR   GO; GO:0030054; C:cell junction; ISS:UniProtKB.
DR   GO; GO:0071944; C:cell periphery; ISS:UniProtKB.
DR   GO; GO:0031253; C:cell projection membrane; IDA:MGI.
DR   GO; GO:0005911; C:cell-cell junction; IDA:BHF-UCL.
DR   GO; GO:0005813; C:centrosome; IDA:BHF-UCL.
DR   GO; GO:0036064; C:ciliary basal body; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000791; C:euchromatin; IDA:BHF-UCL.
DR   GO; GO:0005916; C:fascia adherens; IDA:MGI.
DR   GO; GO:0016600; C:flotillin complex; IDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0014704; C:intercalated disc; IDA:MGI.
DR   GO; GO:0030027; C:lamellipodium; IDA:MGI.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:MGI.
DR   GO; GO:0016020; C:membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031528; C:microvillus membrane; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0099092; C:postsynaptic density, intracellular component; IDA:SynGO.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:SynGO.
DR   GO; GO:0098831; C:presynaptic active zone cytoplasmic component; IDA:SynGO.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:SynGO.
DR   GO; GO:0032991; C:protein-containing complex; ISO:MGI.
DR   GO; GO:0032993; C:protein-DNA complex; ISS:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ComplexPortal.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IDA:SynGO.
DR   GO; GO:0034750; C:Scrib-APC-beta-catenin complex; IDA:BHF-UCL.
DR   GO; GO:0000922; C:spindle pole; IEA:UniProtKB-SubCell.
DR   GO; GO:0045202; C:synapse; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL.
DR   GO; GO:1990909; C:Wnt signalosome; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030018; C:Z disc; IDA:MGI.
DR   GO; GO:0045294; F:alpha-catenin binding; IDA:MGI.
DR   GO; GO:0045296; F:cadherin binding; IPI:CAFA.
DR   GO; GO:0003682; F:chromatin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:1990226; F:histone methyltransferase binding; IPI:BHF-UCL.
DR   GO; GO:0070411; F:I-SMAD binding; IEA:Ensembl.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0016922; F:nuclear receptor binding; IPI:UniProtKB.
DR   GO; GO:0003676; F:nucleic acid binding; EXP:DisProt.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IDA:MGI.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0001221; F:transcription coregulator binding; IPI:BHF-UCL.
DR   GO; GO:0001222; F:transcription corepressor binding; IEA:Ensembl.
DR   GO; GO:0044325; F:transmembrane transporter binding; IEA:Ensembl.
DR   GO; GO:0090425; P:acinar cell differentiation; IMP:MGI.
DR   GO; GO:0034333; P:adherens junction assembly; ISS:UniProtKB.
DR   GO; GO:0034332; P:adherens junction organization; IMP:MGI.
DR   GO; GO:0048513; P:animal organ development; IMP:MGI.
DR   GO; GO:0009948; P:anterior/posterior axis specification; IMP:MGI.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IMP:MGI.
DR   GO; GO:0036520; P:astrocyte-dopaminergic neuron signaling; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0045453; P:bone resorption; IMP:MGI.
DR   GO; GO:0001569; P:branching involved in blood vessel morphogenesis; IMP:MGI.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IMP:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:CAFA.
DR   GO; GO:0044338; P:canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation; IMP:MGI.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; TAS:DFLAT.
DR   GO; GO:0060947; P:cardiac vascular smooth muscle cell differentiation; TAS:DFLAT.
DR   GO; GO:0007155; P:cell adhesion; ISS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IMP:MGI.
DR   GO; GO:0001708; P:cell fate specification; IMP:MGI.
DR   GO; GO:0048469; P:cell maturation; IDA:MGI.
DR   GO; GO:0000902; P:cell morphogenesis; IMP:MGI.
DR   GO; GO:0008283; P:cell population proliferation; IMP:MGI.
DR   GO; GO:0098609; P:cell-cell adhesion; IMP:MGI.
DR   GO; GO:0044331; P:cell-cell adhesion mediated by cadherin; IEA:Ensembl.
DR   GO; GO:0007160; P:cell-matrix adhesion; IMP:MGI.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0071681; P:cellular response to indole-3-methanol; ISS:UniProtKB.
DR   GO; GO:0022009; P:central nervous system vasculogenesis; IMP:MGI.
DR   GO; GO:0007268; P:chemical synaptic transmission; IMP:MGI.
DR   GO; GO:0002062; P:chondrocyte differentiation; IMP:MGI.
DR   GO; GO:0060982; P:coronary artery morphogenesis; TAS:DFLAT.
DR   GO; GO:0061550; P:cranial ganglion development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1904888; P:cranial skeletal system development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006351; P:DNA-templated transcription; IMP:MGI.
DR   GO; GO:1990791; P:dorsal root ganglion development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IMP:MGI.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IMP:MGI.
DR   GO; GO:0007398; P:ectoderm development; IMP:MGI.
DR   GO; GO:0000578; P:embryonic axis specification; IDA:MGI.
DR   GO; GO:1990403; P:embryonic brain development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IMP:MGI.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; IMP:MGI.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IDA:MGI.
DR   GO; GO:0035050; P:embryonic heart tube development; IMP:MGI.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IMP:MGI.
DR   GO; GO:0048568; P:embryonic organ development; IMP:MGI.
DR   GO; GO:0036023; P:embryonic skeletal limb joint morphogenesis; IGI:BHF-UCL.
DR   GO; GO:0001706; P:endoderm formation; IMP:MGI.
DR   GO; GO:0001711; P:endodermal cell fate commitment; IMP:MGI.
DR   GO; GO:0061154; P:endothelial tube morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060983; P:epicardium-derived cardiac vascular smooth muscle cell differentiation; TAS:DFLAT.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030855; P:epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0060742; P:epithelial cell differentiation involved in prostate gland development; IMP:MGI.
DR   GO; GO:0060767; P:epithelial cell proliferation involved in prostate gland development; IMP:MGI.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IMP:MGI.
DR   GO; GO:0060856; P:establishment of blood-brain barrier; IMP:MGI.
DR   GO; GO:1990963; P:establishment of blood-retinal barrier; IMP:MGI.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0061198; P:fungiform papilla formation; IMP:MGI.
DR   GO; GO:0001702; P:gastrulation with mouth forming second; IMP:MGI.
DR   GO; GO:0010467; P:gene expression; IMP:MGI.
DR   GO; GO:0035112; P:genitalia morphogenesis; IMP:MGI.
DR   GO; GO:0007403; P:glial cell fate determination; IDA:MGI.
DR   GO; GO:0022405; P:hair cycle process; IMP:MGI.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IMP:MGI.
DR   GO; GO:0060789; P:hair follicle placode formation; IMP:MGI.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0030097; P:hemopoiesis; IDA:MGI.
DR   GO; GO:0030902; P:hindbrain development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0021854; P:hypothalamus development; IMP:MGI.
DR   GO; GO:0001701; P:in utero embryonic development; IMP:MGI.
DR   GO; GO:0001822; P:kidney development; IMP:MGI.
DR   GO; GO:0021819; P:layer formation in cerebral cortex; IMP:MGI.
DR   GO; GO:0002089; P:lens morphogenesis in camera-type eye; IMP:MGI.
DR   GO; GO:0060173; P:limb development; IMP:MGI.
DR   GO; GO:0060479; P:lung cell differentiation; IMP:MGI.
DR   GO; GO:0030324; P:lung development; IMP:MGI.
DR   GO; GO:0060487; P:lung epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0060492; P:lung induction; IMP:MGI.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IMP:MGI.
DR   GO; GO:0030539; P:male genitalia development; IMP:MGI.
DR   GO; GO:0000165; P:MAPK cascade; IGI:MGI.
DR   GO; GO:0010463; P:mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IMP:MGI.
DR   GO; GO:0072497; P:mesenchymal stem cell differentiation; IMP:MGI.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; ISS:UniProtKB.
DR   GO; GO:0060485; P:mesenchyme development; TAS:DFLAT.
DR   GO; GO:0072132; P:mesenchyme morphogenesis; TAS:DFLAT.
DR   GO; GO:0003338; P:metanephros morphogenesis; IMP:MGI.
DR   GO; GO:0030901; P:midbrain development; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1904948; P:midbrain dopaminergic neuron differentiation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0016331; P:morphogenesis of embryonic epithelium; IMP:MGI.
DR   GO; GO:0051450; P:myoblast proliferation; IMP:MGI.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:BHF-UCL.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IMP:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:ComplexPortal.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:MGI.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; IMP:MGI.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:MGI.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0003340; P:negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis; IDA:MGI.
DR   GO; GO:0045976; P:negative regulation of mitotic cell cycle, embryonic; IMP:UniProtKB.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IGI:MGI.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; IMP:MGI.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; IMP:MGI.
DR   GO; GO:1903377; P:negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0033234; P:negative regulation of protein sumoylation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ComplexPortal.
DR   GO; GO:0072079; P:nephron tubule formation; IMP:MGI.
DR   GO; GO:0001840; P:neural plate development; IDA:MGI.
DR   GO; GO:0007405; P:neuroblast proliferation; IGI:MGI.
DR   GO; GO:0030182; P:neuron differentiation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0048664; P:neuron fate determination; IMP:MGI.
DR   GO; GO:0001764; P:neuron migration; IGI:MGI.
DR   GO; GO:1990138; P:neuron projection extension; ISS:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IMP:MGI.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IMP:MGI.
DR   GO; GO:0048599; P:oocyte development; IGI:MGI.
DR   GO; GO:0001649; P:osteoblast differentiation; IMP:MGI.
DR   GO; GO:0030316; P:osteoclast differentiation; IMP:MGI.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060066; P:oviduct development; IMP:MGI.
DR   GO; GO:0031016; P:pancreas development; IMP:MGI.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:1905555; P:positive regulation of blood vessel branching; IEA:Ensembl.
DR   GO; GO:0061047; P:positive regulation of branching involved in lung morphogenesis; IMP:MGI.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:2000017; P:positive regulation of determination of dorsal identity; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IMP:MGI.
DR   GO; GO:0030858; P:positive regulation of epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IMP:MGI.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISO:MGI.
DR   GO; GO:0045743; P:positive regulation of fibroblast growth factor receptor signaling pathway; IMP:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:MGI.
DR   GO; GO:0010909; P:positive regulation of heparan sulfate proteoglycan biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0034112; P:positive regulation of homotypic cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IGI:MGI.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IMP:MGI.
DR   GO; GO:2000288; P:positive regulation of myoblast proliferation; IMP:MGI.
DR   GO; GO:2000179; P:positive regulation of neural precursor cell proliferation; IMP:UniProtKB.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IMP:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:1901331; P:positive regulation of odontoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:MGI.
DR   GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IMP:CACAO.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; IMP:MGI.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IMP:MGI.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0008104; P:protein localization; IMP:MGI.
DR   GO; GO:0034394; P:protein localization to cell surface; ISS:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IMP:MGI.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0090279; P:regulation of calcium ion import; ISS:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IDA:MGI.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IDA:MGI.
DR   GO; GO:0030997; P:regulation of centriole-centriole cohesion; ISS:UniProtKB.
DR   GO; GO:0070602; P:regulation of centromeric sister chromatid cohesion; IMP:BHF-UCL.
DR   GO; GO:0030856; P:regulation of epithelial cell differentiation; IMP:MGI.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:MGI.
DR   GO; GO:0031641; P:regulation of myelination; IMP:MGI.
DR   GO; GO:0072182; P:regulation of nephron tubule epithelial cell differentiation; IMP:UniProtKB.
DR   GO; GO:0050767; P:regulation of neurogenesis; NAS:ComplexPortal.
DR   GO; GO:0045667; P:regulation of osteoblast differentiation; IMP:MGI.
DR   GO; GO:0045670; P:regulation of osteoclast differentiation; IMP:MGI.
DR   GO; GO:2000008; P:regulation of protein localization to cell surface; ISS:UniProtKB.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0003266; P:regulation of secondary heart field cardioblast proliferation; IDA:MGI.
DR   GO; GO:0048660; P:regulation of smooth muscle cell proliferation; ISS:UniProtKB.
DR   GO; GO:0051963; P:regulation of synapse assembly; IDA:SynGO.
DR   GO; GO:0042129; P:regulation of T cell proliferation; IMP:MGI.
DR   GO; GO:0051884; P:regulation of timing of anagen; IDA:CAFA.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0072053; P:renal inner medulla development; IMP:MGI.
DR   GO; GO:0072054; P:renal outer medulla development; IMP:MGI.
DR   GO; GO:0072033; P:renal vesicle formation; IMP:MGI.
DR   GO; GO:0032355; P:response to estradiol; ISS:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IMP:MGI.
DR   GO; GO:0043588; P:skin development; IMP:MGI.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IMP:MGI.
DR   GO; GO:0072089; P:stem cell proliferation; IMP:MGI.
DR   GO; GO:0061549; P:sympathetic ganglion development; IMP:UniProtKB.
DR   GO; GO:0050808; P:synapse organization; IMP:MGI.
DR   GO; GO:0097091; P:synaptic vesicle clustering; IDA:SynGO.
DR   GO; GO:0048489; P:synaptic vesicle transport; IMP:MGI.
DR   GO; GO:0030217; P:T cell differentiation; IMP:MGI.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IMP:MGI.
DR   GO; GO:0048538; P:thymus development; IMP:MGI.
DR   GO; GO:0001894; P:tissue homeostasis; IMP:MGI.
DR   GO; GO:0060440; P:trachea formation; IMP:MGI.
DR   GO; GO:0060439; P:trachea morphogenesis; IMP:MGI.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0001944; P:vasculature development; IMP:MGI.
DR   GO; GO:0001570; P:vasculogenesis; IMP:MGI.
DR   GO; GO:0003223; P:ventricular compact myocardium morphogenesis; TAS:DFLAT.
DR   CDD; cd21724; CTNNAbd_CTNNB1; 1.
DR   DisProt; DP00341; -.
DR   FunFam; 1.25.10.10:FF:000015; Catenin beta-1; 1.
DR   Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1.
DR   IDEAL; IID50011; -.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000225; Armadillo.
DR   InterPro; IPR013284; Beta-catenin.
DR   PANTHER; PTHR45976; ARMADILLO SEGMENT POLARITY PROTEIN; 1.
DR   Pfam; PF00514; Arm; 4.
DR   PRINTS; PR01869; BCATNINFAMLY.
DR   SMART; SM00185; ARM; 12.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   PROSITE; PS50176; ARM_REPEAT; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Cell adhesion; Cell junction;
KW   Cell membrane; Cell projection; Cytoplasm; Cytoskeleton; Glycoprotein;
KW   Membrane; Neurogenesis; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; S-nitrosylation; Synapse; Transcription; Transcription regulation;
KW   Ubl conjugation; Wnt signaling pathway.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   CHAIN           2..781
FT                   /note="Catenin beta-1"
FT                   /id="PRO_0000064272"
FT   REPEAT          151..191
FT                   /note="ARM 1"
FT   REPEAT          193..234
FT                   /note="ARM 2"
FT   REPEAT          235..276
FT                   /note="ARM 3"
FT   REPEAT          277..318
FT                   /note="ARM 4"
FT   REPEAT          319..360
FT                   /note="ARM 5"
FT   REPEAT          361..389
FT                   /note="ARM 6"
FT   REPEAT          400..441
FT                   /note="ARM 7"
FT   REPEAT          442..484
FT                   /note="ARM 8"
FT   REPEAT          489..530
FT                   /note="ARM 9"
FT   REPEAT          531..571
FT                   /note="ARM 10"
FT   REPEAT          594..636
FT                   /note="ARM 11"
FT   REPEAT          637..666
FT                   /note="ARM 12"
FT   REGION          2..23
FT                   /note="Interaction with VCL"
FT                   /evidence="ECO:0000269|PubMed:20086044"
FT   REGION          34..57
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          156..178
FT                   /note="Interaction with BCL9"
FT                   /evidence="ECO:0000250"
FT   REGION          720..781
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          772..781
FT                   /note="Interaction with SCRIB"
FT                   /evidence="ECO:0000269|PubMed:19458197"
FT   COMPBIAS        734..745
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         23
FT                   /note="Phosphoserine; by GSK3-beta; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         29
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         33
FT                   /note="Phosphoserine; by GSK3-beta and HIPK2"
FT                   /evidence="ECO:0000269|PubMed:20307497"
FT   MOD_RES         37
FT                   /note="Phosphoserine; by GSK3-beta and HIPK2"
FT                   /evidence="ECO:0000269|PubMed:20307497"
FT   MOD_RES         41
FT                   /note="Phosphothreonine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         45
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         49
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         64
FT                   /note="Phosphotyrosine; by PTK6"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         142
FT                   /note="Phosphotyrosine; by FYN and PTK6"
FT                   /evidence="ECO:0000269|PubMed:12640114"
FT   MOD_RES         191
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         246
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         331
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         333
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         552
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:20361929,
FT                   ECO:0007744|PubMed:17242355"
FT   MOD_RES         556
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P35222"
FT   MOD_RES         619
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000269|PubMed:20705246"
FT   MOD_RES         675
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   CARBOHYD        23
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q96S06"
FT   MUTAGEN         8
FT                   /note="M->P: Loss of interaction with VCL."
FT                   /evidence="ECO:0000269|PubMed:20086044"
FT   MUTAGEN         33
FT                   /note="S->A: Abolished HIPK2-mediated proteasomal
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:20307497"
FT   MUTAGEN         37
FT                   /note="S->A: Abolished HIPK2-mediated proteasomal
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:20307497"
FT   MUTAGEN         552
FT                   /note="S->A: Abolishes AMPK-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:20361929"
FT   CONFLICT        371
FT                   /note="T -> I (in Ref. 2; BAB31250)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        478
FT                   /note="A -> T (in Ref. 2; BAB31250)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        487
FT                   /note="L -> F (in Ref. 2; BAB31250)"
FT                   /evidence="ECO:0000305"
FT   HELIX           85..88
FT                   /evidence="ECO:0007829|PDB:4ONS"
FT   HELIX           90..98
FT                   /evidence="ECO:0007829|PDB:4ONS"
FT   HELIX           100..102
FT                   /evidence="ECO:0007829|PDB:4ONS"
FT   HELIX           121..141
FT                   /evidence="ECO:0007829|PDB:1DOW"
FT   TURN            145..148
FT                   /evidence="ECO:0007829|PDB:1DOW"
FT   TURN            150..152
FT                   /evidence="ECO:0007829|PDB:1I7W"
FT   HELIX           153..160
FT                   /evidence="ECO:0007829|PDB:1I7W"
FT   STRAND          161..164
FT                   /evidence="ECO:0007829|PDB:1JPP"
FT   STRAND          166..168
FT                   /evidence="ECO:0007829|PDB:4EVP"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:4EVP"
FT   HELIX           172..178
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           182..189
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   STRAND          192..194
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           195..204
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           208..221
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           225..233
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           236..242
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           243..245
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           249..265
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           269..275
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           278..284
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           285..287
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           291..305
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           309..317
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           320..330
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           334..347
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           353..359
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           362..367
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   TURN            368..371
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           375..389
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           399..408
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           414..428
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           432..440
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           443..454
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           458..471
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   STRAND          473..475
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           478..487
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           491..496
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           504..517
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           521..523
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           524..529
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           532..547
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           566..580
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           584..592
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           596..602
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           608..621
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           625..633
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   TURN            634..636
FT                   /evidence="ECO:0007829|PDB:3OUX"
FT   HELIX           637..643
FT                   /evidence="ECO:0007829|PDB:4EV8"
FT   HELIX           649..661
FT                   /evidence="ECO:0007829|PDB:4EV8"
SQ   SEQUENCE   781 AA;  85471 MW;  D708F170A3FBED6E CRC64;
     MATQADLMEL DMAMEPDRKA AVSHWQQQSY LDSGIHSGAT TTAPSLSGKG NPEEEDVDTS
     QVLYEWEQGF SQSFTQEQVA DIDGQYAMTR AQRVRAAMFP ETLDEGMQIP STQFDAAHPT
     NVQRLAEPSQ MLKHAVVNLI NYQDDAELAT RAIPELTKLL NDEDQVVVNK AAVMVHQLSK
     KEASRHAIMR SPQMVSAIVR TMQNTNDVET ARCTAGTLHN LSHHREGLLA IFKSGGIPAL
     VKMLGSPVDS VLFYAITTLH NLLLHQEGAK MAVRLAGGLQ KMVALLNKTN VKFLAITTDC
     LQILAYGNQE SKLIILASGG PQALVNIMRT YTYEKLLWTT SRVLKVLSVC SSNKPAIVEA
     GGMQALGLHL TDPSQRLVQN CLWTLRNLSD AATKQEGMEG LLGTLVQLLG SDDINVVTCA
     AGILSNLTCN NYKNKMMVCQ VGGIEALVRT VLRAGDREDI TEPAICALRH LTSRHQEAEM
     AQNAVRLHYG LPVVVKLLHP PSHWPLIKAT VGLIRNLALC PANHAPLREQ GAIPRLVQLL
     VRAHQDTQRR TSMGGTQQQF VEGVRMEEIV EGCTGALHIL ARDVHNRIVI RGLNTIPLFV
     QLLYSPIENI QRVAAGVLCE LAQDKEAAEA IEAEGATAPL TELLHSRNEG VATYAAAVLF
     RMSEDKPQDY KKRLSVELTS SLFRTEPMAW NETADLGLDI GAQGEALGYR QDDPSYRSFH
     SGGYGQDALG MDPMMEHEMG GHHPGADYPV DGLPDLGHAQ DLMDGLPPGD SNQLAWFDTD
     L
//
